Blood Test Study to Detect Early Blood Cancers
Tests a blood sample screen for blood cancers in adults, including people at risk.
Plain-language title generated from the registry record
Registry title: Early Detection and Screening of Hematological Malignancies - SANGUINE
Key facts
- Where
- Vilnius, LithuaniaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with certain blood cancers or early blood conditions who have not yet been treated, adults at risk, and people with no cancer as controls.
- Age
- 18 years or older.
- Sex
- Women and men can join.
- Disease stage
- Multiple myeloma, smoldering multiple myeloma, MGUS, Hodgkin lymphoma, diffuse large B cell lymphoma, follicular lymphoma, marginal zone lymphoma, acute myeloid leukemia or myelodysplastic syndrome, diagnosed or being followed. People at risk are first-degree relatives or people aged 65 or older.
- Earlier treatment
- Patients must not have had any treatment yet for the condition. Exceptions: DLBCL changed from follicular or marginal zone lymphoma, and AML following MDS or MPN, treated for the first disease.
Main reasons for not taking part
- Another current cancer, or another cancer within the last 2 years (skin cancer without melanoma or carcinoma in situ is fine if fully removed)
- Acute promyelocytic leukemia (APL)
- Active autoimmune disease needing immune-suppressing treatment
- Known HIV-positive
- Known active hepatitis A, B or C, or past hepatitis C
Read by machine on 9 November 2026.
Where in Lithuania
- Vilnus University Hospital Santaros Klinikos (VULSK)Vilnius, LithuaniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- JaxBio Ltd
- Trial code
- NCT05735704
- Record updated
- 15 October 2026
- Original description
This is a multicenter, open-label, non-interventional controlled study to identify and characterize the epigenetic signatures for a set of hematological malignancies: Multiple myeloma (MM), pre-MM conditions [smoldering MM (SMM) and monoclonal gammopathy of undetermined significance (MGUS)], Hodgkin lymphoma (HL), diffuse large B cell lymphoma (DLBCL), Follicular lymphoma (FL), Marginal Zone lymphomas (MZL), acute myeloid leukemia (AML)*, myelodysplastic syndrome (MDS), subjects at risk and control subjects with no malignant disease.Read full original descriptionShow less
Early Detection and Screening of Hematological Malignancies - SANGUINE
This is a multicenter, open-label, non-interventional controlled study to identify and characterize the epigenetic signatures for a set of hematological malignancies: Multiple myeloma (MM), pre-MM conditions [smoldering MM (SMM) and monoclonal gammopathy of undetermined significance (MGUS)], Hodgkin lymphoma (HL), diffuse large B cell lymphoma (DLBCL), Follicular lymphoma (FL), Marginal Zone lymphomas (MZL), acute myeloid leukemia (AML)*, myelodysplastic syndrome (MDS), subjects at risk and control subjects with no malignant disease.
*Patients with a diagnosis of acute promyelocytic leukemia (APL) are not included
Inclusion: General criteria for all study populations:; Male and female subjects ≥18 years of age; Ability to understand and willingness to sign a written informed consent document; For Patients with hematological malignancies:; Patients who have been diagnosed, have measurable disease, and/or are being monitored/followed up due to one of the following conditions: MM, pre-MM conditions (SMM and MGUS), HL, DLBCL, FL, MZL, AML, MDS that did not yet undergo any treatment; NOTE:; Patients diagnosed with DLBCL that is transformed from FL or MZL, and patients diagnosed with AML secondary to MDS or MPN, who were treated for their primary disease (FL/MZL/MDS/MPN) before study enrollment, are eligible; For subjects at risk for developing the investigated hematological malignancies:; First-degree relatives; AND /OR; Elderly subjects ≥ 65 years of age.
Exclusion: Patients/subjects with active inflammatory autoimmune disease that requires treatment with immunosuppressive/ immunomodulation agents; Patients/subjects with current co-diagnosis of another type of cancer; Patients/subjects with a known active or prior cancer (other than defined as study population), occurring within the last 2 years (even if considered to be in complete remission). Patients/subjects with non- melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection; Patients/subjects with known human immunodeficiency virus (HIV) positive; Patients/subjects with known active Hepatitis A/B/C or past hepatitis C; Patients with a diagnosis of acute promyelocytic leukemia (APL); Subjects that are likely to be noncompliant with the protocol, or felt to be unsuitable by the investigator for any other reason.